Vernal Keratoconjunctivitis (VKC) is an uncommon chronic allergic inflammatory illness that affects the cornea and conjunctiva of the eye and is usually linked with secondary keratopathy. The growth of enormous papillae, generally in the upper tarsal conjunctiva of a person, is a symptom of vernal keratoconjunctivitis. It might appear in the corneoscleral limbus of the conjunctiva in rare situations. The condition is seasonal and mostly affects children and teenagers.
While vernal keratoconjunctivitis has a low prevalence rate in regions having cold climates such as North America and Northern Europe (of around 1 in 5000 eye disease cases), it has a relatively high frequency in other parts of the world with warm and arid climates. In tropical regions, such as India and Sub-Saharan Africa, Vernal Keratoconjunctivitis Market accounts for 3% of serious ophthalmic diseases. It primarily affects males aged 5 to 25 years and is thought to diminish with the advent of puberty; nevertheless, occurrences of VKC have been observed in septuagenarian individuals. Vernal keratoconjunctivitis is more common in dry and warmer areas, such as the Mediterranean, Japan, Central Africa, South America, and India. The increased prevalence of vernal keratoconjunctivitis and other allergic eye illnesses found throughout the world is a major factor driving the growth of the vernal keratoconjunctivitis treatment market.
